Roche to file T-DM1 breast cancer drug on good data
ZURICH (Reuters) - Roche said patients with an aggressive type of breast cancer lived longer after taking its experimental "armed antibody" drug without the disease worsening than those on a mix of GlaxoSmithKline drug Tykerb and Roche's Xeloda. The positive results from the first Phase III trial of the medicine - dubbed T-DM1 - clears the way for it to be submitted to European and U.S. authorities for approval this year, boosting prospects for a key asset in the Swiss firm's pipeline. WestLB analyst Oliver Kaemmerer, who sees peak sales potential for T-DM1 of around 1 billion Swiss francs ... read more..
source:http://yhoo.it/H7SKtl
No comments:
Post a Comment